European breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.2% during the forecast period. The market is mainly driven due to the high prevalence of breast cancer within European countries that include UK, Germany, Italy Spain, and others. These countries play a significant role in growth including awareness programs, the introduction of new imaging technologies and government expenditure on breast cancer diagnosis and treatment. The European Breast Cancer Coalition works to raise awareness of breast cancer. The European Commission launched the European Commission Initiative on Breast Cancer (ECIBC) in 2012 to ensure that all breast cancer care processes are performed with quality and correctly in all citizens in Europe. The objective of ECIBC was to establish a voluntary European quality assurance scheme for breast cancer services including screening, diagnosis, treatment, rehabilitation, survivorship care and palliative care. These initiatives enable the growth and diagnosis rates that influenced the breast cancer market.
European breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
To Request a Sample of our Report on European Breast Cancer Diagnostics And Therapeutics Market: https://www.omrglobal.com/request-sample/european-breast-cancer-diagnostics-therapeutics-market
European Breast Cancer Diagnostics And Therapeutics Market Segmentation
By Cancer Type
- Ductal Carcinoma In-Situ (DCIS)
- Invasive Ductal Carcinoma (IDC)
- Triple Negative Breast Cancer (TNBC)
- Inflammatory Breast Cancer
- Others (Invasive lobular carcinoma)
By Diagnostics
- Mammography
- Biopsy
- PET/CET
- Ultrasound
- Others (MRI)
By Therapeutics
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Others (Radiation Therapy, Surgery)
A full Report of European Breast Cancer Diagnostics And Therapeutics Market is Available @ https://www.omrglobal.com/industry-reports/european-breast-cancer-diagnostics-therapeutics-market
Regional Analysis
- UK
- Germany
- France
- Italy
- Spain
Rest of Europe
Company Profiles
- Agendia NV
- AstraZeneca PLC
- Bayer AG
- GlaxoSmithKline PLC
- Mylan NV
- Merck & Co., Inc.
- Novartis International AG
- Hoffmann-La Roche AG
- Sanofi S.A.
- Siemens Healthcare GmbH
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
